Literature DB >> 21993364

The ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity.

Renée M Ned1, Ajay Yesupriya, Giuseppina Imperatore, Diane T Smelser, Ramal Moonesinghe, Man-Huei Chang, Nicole F Dowling.   

Abstract

BACKGROUND: The insertion/deletion (I/D) variant (rs4646994) of the angiotensin I-converting enzyme (ACE) gene is one of the most studied polymorphisms in relation to blood pressure and essential hypertension in humans. The evidence to date, however, on an association of this variant with blood pressure-related outcomes has been inconclusive.
METHODS: We examined 5,561 participants of the Third National Health and Nutrition Examination Survey (NHANES III), a population-based and nationally representative survey of the United States, who were ≥20 years of age and who self-identified as non-Hispanic white, non-Hispanic black, or Mexican American. Within each race/ethnicity, we assessed genetic associations of the I/D variant with systolic blood pressure (SBP), diastolic blood pressure (DBP), and hypertension, as well as genotype-sex interactions, in four genetic models (additive, dominant, recessive, and codominant).
RESULTS: The frequency of the I/D variant differed significantly by race/ethnicity (P = 0.001). Among non-Hispanic blacks, the D allele was significantly associated (P < 0.05) with increased SBP in additive and dominant covariate-adjusted models and was also associated with increased DBP in dominant models when participants taking ACE inhibitors were excluded from the analyses. No other significant associations were observed in any race/ethnic group. Significant genotype-sex interactions were detected among Mexican Americans, for whom positive associations with SBP and hypertension were seen among females, but not males.
CONCLUSIONS: This study gives limited support for association of the ACE I/D variant with blood pressure and for sex-specific effects among particular race/ethnic groups, though we cannot rule out the role of genetic or environmental interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993364     DOI: 10.1038/ajh.2011.182

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  12 in total

1.  Case-control association study of polymorphisms in the angiotensinogen and angiotensin-converting enzyme genes and coronary artery disease and systemic artery hypertension in African-Brazilians and Caucasian-Brazilians.

Authors:  Ricardo Bonfim-Silva; Larissa Oliveira Guimarães; Jandson Souza Santos; Jaqueline Fagundes Pereira; Ana Angélica Leal Barbosa; Domingos Lazaro Souza Rios
Journal:  J Genet       Date:  2016-03       Impact factor: 1.166

2.  Genetic influence on exercise-induced changes in physical function among mobility-limited older adults.

Authors:  Thomas W Buford; Fang-Chi Hsu; Tina E Brinkley; Christy S Carter; Timothy S Church; John A Dodson; Bret H Goodpaster; Mary M McDermott; Barbara J Nicklas; Veronica Yank; Julie A Johnson; Marco Pahor
Journal:  Physiol Genomics       Date:  2014-01-14       Impact factor: 3.107

3.  Association Between M235T-AGT and I/D-ACE Polymorphisms and Carotid Atheromatosis in Hypertensive Patients: A Cross-Sectional Study.

Authors:  Oana Mocan; Elena Buzdugan; Angela Cozma; Daniel Corneliu Leucuta; Dan Radulescu; Lucia Maria Procopciuc
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 4.  Renin angiotensinogen system gene polymorphisms and essential hypertension among people of West African descent: a systematic review.

Authors:  L M Reiter; D L Christensen; A P Gjesing
Journal:  J Hum Hypertens       Date:  2015-11-26       Impact factor: 3.012

5.  Childhood adiposity, adult adiposity, and the ACE gene insertion/deletion polymorphism: evidence of gene-environment interaction effects on adult blood pressure and hypertension status in adulthood.

Authors:  Cong Sun; Anne-Louise Ponsonby; John B Carlin; Minh Bui; Costan G Magnussen; Trudy L Burns; Terho Lehtimaki; Nicole H Wardrop; Markus Juonala; Jorma S A Viikari; Alison J Venn; Olli T Raitakari; Terence Dwyer
Journal:  J Hypertens       Date:  2018-11       Impact factor: 4.844

6.  Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.

Authors:  Rangaprasad Sarangarajan; Robert Winn; Michael A Kiebish; Chas Bountra; Elder Granger; Niven R Narain
Journal:  J Racial Ethn Health Disparities       Date:  2020-09-08

7.  The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients.

Authors:  Denise S Pinheiro; Rodrigo S Santos; Paulo C B Veiga Jardim; Elisangela G Silva; Angela A S Reis; Gustavo R Pedrino; Cirano J Ulhoa
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

8.  Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.

Authors:  Sherry-Ann Brown; Svetlana Zaharova; Peter Mason; Jonathan Thompson; Bicky Thapa; David Ishizawar; Erin Wilkes; Gulrayz Ahmed; Jason Rubenstein; Joyce Sanchez; David Joyce; Balaraman Kalyanaraman; Michael Widlansky
Journal:  Front Cardiovasc Med       Date:  2020-12-04

9.  Interaction of ACE genotype and salt intake on hypertension among Chinese Kazakhs: results from a population-based cross-sectional study.

Authors:  Yuyan Wang; Biao Zhang; Lei Hou; Wei Han; Fang Xue; Yanhong Wang; Yong Tang; Shaohua Liang; Weizhi Wang; Kuliqian Asaiti; Zixing Wang; Yaoda Hu; Lei Wang; Changchun Qiu; Mingtao Zhang; Jingmei Jiang
Journal:  BMJ Open       Date:  2017-05-17       Impact factor: 2.692

10.  Association of Angiotensin I Converting Enzyme Insertion/287 bp Deletion Polymorphisms and Proliferative Prostatic Diseases among Lebanese Men.

Authors:  Asmahan A El Ezzi; Jordan M Clawson; Mohammed A El-Saidi; Wissam R Zaidan; Abigail Kovash; Jeremy Orellana; AnnaKarina Thornock; Ruhul H Kuddus
Journal:  Prostate Cancer       Date:  2020-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.